Stimulation is delivered by the VNS Therapy System(TM), an implantable
generator similar to a cardiac pacemaker .
Words such as "will," "expects," "anticipates," "plans," and similar
expressions are intended to identify these forward-looking statements.

shopping poppy

"Approximately 30 to 40 percent of patients with epilepsy have seizures
that are not controlled by drugs alone, requiring nonpharmacologic treatment
options like VNS Therapy," said Dr. For additional information please
visit us at http://www . The webcast replay will be available from May 23,
2005, 3:00pm EDT until May 30, 2005. For more information, please
visit: www. Aspect's BIS technology
directly measures the effects of anesthetics and sedatives on the
brain.

awareness teenagers

"

ABOUT VNS THERAPY AND CYBERONICS
Cyberonics, Inc.

The Cyberonics VNS Therapy System was
approved by the FDA on July 16, 1997 for use as an adjunctive therapy in
reducing the frequency of seizures in adults and adolescents over 12 years of
age with partial onset seizures that are refractory to antiepileptic
medications. To participate in the call , please
dial 1-800-810-0924 (domestic), 1-913-981-4900 (international), or you
may access the webcast at http://www. The patent application is being filed in conjunction with
major research institutions in the Houston area, with Power3 having an
exclusive license to commercialize the technology involved .

neurological increasing

(Nasdaq: CYBX)
today announced that Vagus Nerve Stimulation (VNS) Therapy has accumulated
more than 100,000 patient years of experience, making it the most widely used
neurostimulation device for the treatment of epilepsy, depression and central
nervous system (CNS) disorders. Expert neurologists , psychiatrists and
more than 1,000 surgeons from leading medical institutions around the world
are at the forefront of neuromodulation, prescribing and implanting VNS
Therapy.

Business Editors/Health/Medical Writers

NEWTON, Mass.

head awareness

In addition to treatment-resistant depression and pharmacoresistant
epilepsy indications, VNS Therapy is at various stages of investigational
clinical studies as a potential treatment for anxiety disorders, Alzheimer's
disease, bulimia and chronic headache/migraine. "The recent approval of VNS as a treatment for
treatment-resistant depression is also important for epilepsy patients,
considering that people with epilepsy also have a high risk of depression and
mood disorders, co-morbidities that can greatly diminish quality of life if
not adequately treated.aspectmedical.com

Power3Medical.

system useful

James W. was founded in 1987 to design , develop and market medical
devices for the long-term treatment of epilepsy, depression and other chronic
treatment-resistant disorders using a unique therapy, vagus nerve stimulation
(VNS).com on the Investor
page, or at http://ccbn.

diseases neurological

The Company
is also investigating how other methods of analyzing brain waves may
aid in the diagnosis and management of neurological diseases,
including depression and Alzheimer's disease. The Company's identified protein biomarkers, drug
targets, and diagnostic tests are targeted toward markets with critical unmet
needs in areas such as breast cancer and neurodegenerative disease.

trak wanderers

useful trak

"
"Global use of implants overall has doubled since the year 2000 , and the
fastest growing category of implants is neurostimulators, devices used to
treat a wide range of CNS disorders, including epilepsy," notes James Cavuoto,
publisher of the Neurotech Business Report. Epilepsy is the second most
prevalent neurological disorder.

Aspect Medical Systems + Boston Scientific Form Strategic Alliance to Develop Brain Monitoring Technology for Diagnosing and Treating Depression + Alzheimer's

The Company's patent-pending technologies are
being used to develop screening and diagnostic tests for the early detection
and treatment of disease.

wanderers security

Eight years after FDA approval as an
adjunctive therapy used to reduce the frequency of seizures in adults and
adolescents over 12 years of age with partial onset seizures that are
refractory to antiepileptic medications, VNS Therapy has been used to treat
more than 32,000 patients worldwide. VNS Therapy is the first implantable
device-based treatment for depression and the first treatment specifically
developed, studied , approved and labeled for treatment-resistant depression. The VNS Therapy System delivers
preprogrammed intermittent mild electrical pulses to the vagus nerve in the
patient's neck 24 hours a day. We believe that patent protection for the specific diagnosis of ALS
will prove to be a strong asset in the Company 's ever growing intellectual
property portfolio, and thereby, serve to enhance shareholder value.

The
Company operates a state-of-the-art proteomics laboratory in The Woodlands,
Texas.

diseases wanderers

For more information on VNS
Therapy for treatment-resistant depression, including the contraindications,
warnings and precautions, see the Physician's and Patient's Manuals and other
information at http://www.
The VNS Therapy System has been approved for sale in the European Economic
Area and in Canada as a treatment for depression in patients with treatment-
resistant or treatment-intolerant major depressive episodes, including
unipolar depression and bipolar disorder (manic depression) since 2001.----Aspect Medical
Systems, Inc.
"The purpose of this blood serum test is to diagnose whether a patient has
ALS and distinguish that from patients who have ALS like symptoms but do not
have ALS," says Ira L. Goldknopf, Chief Scientific Officer of Power3 Medical.

alzheimer increasing

com or call
1-877 -NOW 4 VNS. The Company also intends to
extend the technology to high throughput immunodiagnostics suitable for
clinical laboratories and doctors' offices.

About Power3 Medical Products
Power3 Medical Products, http://www.

wanderers neurological

Wheless, Professor and Chief of
Pediatric Neurology, Le Bonheur Chair in Pediatric Neurology at the University
of Tennessee Health Science Center. "Years of clinical use and more than
100,000 patient years of experience have shown that VNS Therapy is a valuable
long-term treatment option for pharmacoresistant epilepsy with benefits to
patients that improve over time. "Cyberonics is clearly a market
leader in the growing neuromodulation market .

About Boston Scientific Corporation

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range
of interventional medical specialties.bostonscientific."
Power3's test comprises collecting a blood sample from a patient ,
separating the proteins present in the sample, analyzing a panel of protein
biomarkers using proteomic techniques, and determining whether or not the
patient has ALS based on the quantity of the biomarkers in the patient's
sample combined with biostitistical analysis. Power3 assumes no obligation to update forward-looking statements as a
result of new information, future events or otherwise.

treatment poppy

The 100,000 patient years milestone comes on the heels of FDA approval of
VNS Therapy as an adjunctive long-term treatment of chronic or recurrent
depression for patients 18 years of age or older who are experiencing a major
depressive episode and have not had an adequate response to four or more
adequate antidepressant treatments. (Nasdaq: ASPM) and Boston Scientific (NYSE: BSX) have
announced the formation of a strategic alliance to develop brain
monitoring technology for diagnosing and treating depression and
Alzheimer's disease.

Power3 Medical Files Provisional Patent Application for Biomarker-based Method to Diagnose ALS vs. ALS-like Disorders

"
"Neurodegenerative diseases are difficult to diagnose, particularly in
their early stages, because currently there are no objective blood serum tests
available for the early diagnosis of these diseases," said Steven Rash,
chairman and chief executive officer.

head neurological

To date, BIS technology has been used to assess more than 11. This application
is one of 12 provisional patent applications, 9 utility patents pending, and 1
issued patent, owned and/or licensed by Power3. There
are a number of important factors and uncertainties that could cause results
to differ materially from those indicated by these forward-looking statements,
including risks inherent in research and development activities; the ability
to raise sufficient capital and obtain financing for the development
activities; uncertainties associated with regulatory approvals; as well as
other risks detailed from time to time in Power3's reports filed with the
Securities and Exchange Commission, including its Annual Report on Form 10-KSB
for the year ended December 31 , 2003, and its reports on Form 10-QSB and Form
8-K.

useful diseases

The Company's initial market was epilepsy, a
disorder characterized by recurrent seizures. To date, more than 32,000 epilepsy patients in 24 countries have
accumulated over 100,000 patient years of experience using VNS Therapy.com .3
million patients and has been the subject of approximately 1,800
published articles and abstracts. "Our objective is to obtain patent
protection for Power3's intellectual property rights used in tests measuring
changes among groups of biomarkers for the early detection of neurological
diseases.

Contacts:
Steven B.

increasing treatment

Telephone replays will be available by
dialing 1-888-203-1112 (domestic ), or 1-719-457-0820 (international),
access code 1614513. Aspect has OEM agreements with
seven leading manufacturers of patient monitoring systems.PK) announced today that it has filed a provisional
patent application with the United States Patent and Trademark Office for the
Company's first generic, blood-based Lou Gehrig's disease (ALS) specific
diagnostic test.

trak diseases

"
"Once a novel treatment , today VNS Therapy is an important, safe and
effective treatment option for thousands of patients with medically refractory
epilepsy," said Eric Hargis, President and Chief Executive Officer of the
national Epilepsy Foundation. The VNS Therapy System is also approved for sale as a treatment
for epilepsy in all the European Economic Area, Canada, Australia and other
markets.cyberonics.aspectmedical .com.

alzheimers teenagers

T: 281-466-1600

alzheimer useful

com

About Aspect Medical Systems, Inc. BIS technology is installed in
approximately 38 percent of all domestic operating rooms and is
available in more than 160 countries. The application is in support
of the Company's planned second Pre-IDE application to be filed with the
United States Food and Drug Administration (FDA) to seek their guidance on
aspects of the approval process for the diagnostic tests being commercialized
by the Company.

restraint resource

Approximately 75 percent of patients reaching end of service elect to continue
with VNS Therapy, further supporting VNS Therapy's safety and effectiveness
record.
VNS Therapy is at various levels of investigational clinical study as a
potential treatment for anxiety disorders, Alzheimer's disease, chronic
headache /migraine and bulimia. Today, beginning at 12:00pm EDT, the Companies
will host a conference call and live webcast for all interested
parties, including financial analysts, portfolio managers, individual
investors and members of the press.

Aspect Medical Systems, Inc. (Nasdaq: ASPM) is a global market
leader in brain monitoring technology. Blood-based Diagnostic Test Could Provide Means for Early Diagnosis
of Lou Gehrig's disease (ALS)

THE WOODLANDS , Texas, Power3 Medical
Products, Inc.com , is a leading
proteomics company engaged in the discovery of protein footprints, pathways,
and mechanisms of diseases. Any statements in this press release , which are not
statements of historical fact, may be deemed to be forward-looking statements.

alzheimers useful

Cyberonics ' VNS Therapy Surpasses 100 000 Patient Years of Experience

" As part of FDA's approval order, Cyberonics is
required to conduct a 450-patient post-market dosing study and a 1,000-
patient, five-year patient outcome registry. The Company is headquartered in Houston, Texas
and has an office in Brussels , Belgium. (OTC: PWRM.

system increasing

This press release contains "forward-looking" statements, including
statements related to the outcome of certain actions being taken by the
Company and the anticipated timing and nature of filings with the Securities
and Exchange Commission. Rash
Chairman and CEO
Power3 Medical Products, Inc.

free diagnosis

The VNS Therapy System was approved by the FDA on July 15, 2005 "as an
adjunctive long-term treatment for chronic or recurrent depression for
patients 18 years of age and older who are experiencing a major depressive
episode and have not had an adequate response to four or more adequate
antidepressant treatments. For more information,
visit Aspect 's web site at http://www.
The Power3 intellectual property portfolio includes other pending patents ,
provisional patent applications, and research and license agreements with
leading medical research institutions in the areas of cancer, drug resistance,
metabolic syndrome, and neurodegenerative disease .

diagnosis increasing

HOUSTON, Cyberonics, Inc.vnstherapy.
"The test is being developed for use by internists and general neurologists,
to help them refer the patient to an ALS clinic, and for ALS specialists as
well.